Published Online: March 4, 2021. doi:10.1001/jama.2021.3465
Correction: This article was corrected on March 10, 2021, to remove the words “or previously infected” from the second sentence in the third paragraph.
Corresponding Author: John P. Moore, PhD, Weill Cornell Medicine, Cornell University, 1300 York Ave, New York, NY 10065 (jpm2003@med.cornell.edu).
Conflict of Interest Disclosures: None reported.
Editor’s Note: Although preprints are rarely included as references in JAMA articles, in the midst of the COVID-19 pandemic some of the information in this article is based on rapidly developing and emerging science that is only available as preliminary communications on preprint servers.
1.Shen
X , Tang
H , McDanal
C ,
et al. SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral Spike vaccines.
bioRxiv. Published online January 29, 2021. doi:
10.1101/2021.01.27.428516
PubMedGoogle Scholar 2.Garcia-Beltran
WF , Lam
EC , St Denis
K ,
et al. Circulating SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity.
medRxiv. Published online February 18, 2021. doi:
10.1101/2021.02.14.21251704
PubMedGoogle Scholar 6.Madhi
SA , Baillie
V , Cutland
CL ,
et al. Safety and efficacy of the ChAdOx1 nCoV-19 (AZD1222) Covid-19 vaccine against the B.1.351 variant in South Africa.
medRxiv. Published online February 12, 2021. doi:
10.1101/2021.02.10.21251247Google Scholar 10.Stamatatos
L , Czartoski
J , Wan
Y-H ,
et al. Antibodies elicited by SARS-CoV-2 infection and boosted by vaccination neutralize an emerging variant and SARS-CoV-1.
medRxiv. Published online February 8, 2021. doi:
10.1101/2021.02.05.21251182Google Scholar